RxDoctor Payments Data

Gary Silverman, MD

Family Medicine · Vero Beach, FLNPI 1003812025

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 72 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$236
  • Novartis$227
  • Pfizer$132
  • Alnylam Pharmaceuticals Inc.$125
  • GSK$125
  • Merck$109
  • plus $373 from 12 others

What the payments were for

  • Food & beverage$1,27696%
  • Gifts$504%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$25,550
Medicare patients
319
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$52,600
OzempicSemaglutide20$22,143
JanuviaSitagliptin Phosphate14$19,547
XareltoRivaroxaban14$16,543
SymbicortBudesonide/Formoterol Fumarate11$5,912
Breo ElliptaFluticasone/Vilanterol14$4,266
Atorvastatin Calcium270$3,308
Levothyroxine Sodium187$3,183
Rosuvastatin Calcium190$3,092
Metformin Hcl113$1,913
Omeprazole95$1,842
Amlodipine Besylate197$1,626
Pravastatin Sodium103$1,480
Metoprolol Succinate91$1,442
Oxcarbazepine15$1,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$132$52,60058 claims
Novo NordiskOzempic$236$22,14320 claims
MerckJanuvia$109$19,54714 claims
Johnson & JohnsonXarelto$22$16,54314 claims
GSKBreo Ellipta$125$4,26614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →